ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,738.52
-1.78%
US Tech 100
19,620.80
-2.29%
다우존스 지수
42,579.08
-0.99%
Bitcoin
87,459.27
-2.75%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Larimar Therapeutics Inc (LRMR) 시세

Larimar Therapeutics Inc

Larimar Therapeutics Inc (LRMR)

NASDAQ
3.06
-0.12
(-3.77%)
마감 07 3월 6:00AM
15분 지연
3.06
0.00
(0.00%)
시간외 거래: 7:37AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
3.06
매수가
3.00
매도가
3.35
거래량
349,109
3.02 일간 변동폭 3.16
2.522 52주 범위 11.97
market_cap
195.248M
전일 종가
3.18
개장가
3.08
최근 거래 시간
1
@
3.35
마지막 거래 시간
재정 규모
US$ 1,072,224
VWAP
3.0713
평균 볼륨(3m)
763,125
발행 주식
63,806,628
배당수익률
-
주가수익률
-1.71
주당순이익(EPS)
-0.58
매출
-
순이익
-36.95M

Larimar Therapeutics Inc 정보

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
larimartx.com
본부
Wilmington, Delaware, USA
설립됨
-
Larimar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker LRMR. The last closing price for Larimar Therapeutics was US$3.18. Over the last year, Larimar Therapeutics shares have traded in a share price range of US$ 2.522 to US$ 11.97.

Larimar Therapeutics currently has 63,806,628 shares in issue. The market capitalisation of Larimar Therapeutics is US$202.91 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

LRMR 최신 뉴스

추가 뉴스

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
05 2월 2025
LRMR (-3.77%)

Form 8-K - Current report
Edgar (US Regulatory)
28 1월 2025
LRMR (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 1월 2025
LRMR (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 1월 2025
LRMR (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 1월 2025
LRMR (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 1월 2025
LRMR (-3.77%)

Form 8-K - Current report
Edgar (US Regulatory)
10 1월 2025
LRMR (-3.77%)

Form 8-K - Current report
Edgar (US Regulatory)
16 12월 2024
LRMR (-3.77%)

Form 8-K - Current report
Edgar (US Regulatory)
18 11월 2024
LRMR (-3.77%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.113.728813559322.953.192.5224845862.91422095CS
4-0.78-20.31253.843.88992.5224833343.14066592CS
12-3.37-52.41057542776.436.4852.5227631253.92150005CS
26-5.86-65.69506726468.929.52.5227455275.68128091CS
52-8.71-74.001699235311.7711.972.5226073416.68783328CS
156-0.88-22.33502538073.9413.681.533438046.10432776CS
260-8.94-74.51225.871.532522386.74147958CS

LRMR - Frequently Asked Questions (FAQ)

What is the current Larimar Therapeutics share price?
The current share price of Larimar Therapeutics is US$ 3.06
How many Larimar Therapeutics shares are in issue?
Larimar Therapeutics has 63,806,628 shares in issue
What is the market cap of Larimar Therapeutics?
The market capitalisation of Larimar Therapeutics is USD 202.91M
What is the 1 year trading range for Larimar Therapeutics share price?
Larimar Therapeutics has traded in the range of US$ 2.522 to US$ 11.97 during the past year
What is the PE ratio of Larimar Therapeutics?
The price to earnings ratio of Larimar Therapeutics is -1.71
What is the reporting currency for Larimar Therapeutics?
Larimar Therapeutics reports financial results in USD
What is the latest annual profit for Larimar Therapeutics?
The latest annual profit of Larimar Therapeutics is USD -36.95M
What is the registered address of Larimar Therapeutics?
The registered address for Larimar Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Larimar Therapeutics website address?
The website address for Larimar Therapeutics is larimartx.com
Which industry sector does Larimar Therapeutics operate in?
Larimar Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
357.55M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
690.72M
LZMHLZ Technology Holdings Ltd
US$ 9.79
(33.56%)
576.65k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 14.62
(33.39%)
15.92M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
134.05M
BLNEEastside Distilling Inc
US$ 0.7846
(-89.40%)
12.25k
ACONAclarion Inc
US$ 1.5501
(-77.86%)
51.53M
ELABPMGC Holdings Inc
US$ 0.7132
(-42.02%)
1.51M
SNBRSleep Number Corporation
US$ 7.49
(-41.89%)
4.56M
CCLDCareCloud Inc
US$ 2.0904
(-33.00%)
1.23M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
694.71M
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
359.59M
NVDANVIDIA Corporation
US$ 110.57
(-5.74%)
321.25M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
135.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.75
(-11.38%)
134.95M

LRMR Discussion

게시물 보기
tw0122 tw0122 8 월 전
LRMR above $9 momentarily
👍️0
Monksdream Monksdream 10 월 전
LRMR under $10

👍️0
Monksdream Monksdream 11 월 전
LRMR under $10
👍️0
Monksdream Monksdream 1 년 전
LRMR new 52 week high
👍️0
Monksdream Monksdream 1 년 전
LRMR new 52=week high
👍️0
AJ Freely AJ Freely 2 년 전
$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40
👍️0
magacrew2020 magacrew2020 2 년 전
could probably get through approval on just 25 mg if they are going to approve reta
👍️0
subslover subslover 3 년 전
The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.
👍️0
JJJ54 JJJ54 3 년 전
I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.
👍️0
DarkPool DarkPool 3 년 전
Interesting.
👍️0
oxnous oxnous 4 년 전
Waking up . But volume should be higher.
👍️0
DewDiligence DewDiligence 5 년 전
LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.
👍️0
casenumber casenumber 5 년 전
Large chunks are being gobbled
Whales are lurking around?
👍️0
subslover subslover 5 년 전
The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/
👍️0
casenumber casenumber 5 년 전
Volume!
👍️0
ClayTrader ClayTrader 5 년 전
* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 년 전
* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 년 전
News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?
👍️0
Fat Thor Fat Thor 5 년 전
Like I said at .67 cents
👍️0
ClayTrader ClayTrader 5 년 전
* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 년 전
Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!
👍️0
ClayTrader ClayTrader 5 년 전
* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 년 전
Over a buck soon when ticker change completed....
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
exactly is great
👍️0
Fat Thor Fat Thor 5 년 전
Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
R/Split coming per 8k today
👍️0
Fat Thor Fat Thor 5 년 전
December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.
👍️0
casenumber casenumber 5 년 전
Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
👍️0
casenumber casenumber 5 년 전
Shorts covering.. they have to before it gets out of control once the merger is official...
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
10 day MA live chart huge oversold,safe here now,will recover nice
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
bought 3k at 6391
👍️0
Fat Thor Fat Thor 5 년 전
Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN



👍️0
alchemytrader alchemytrader 5 년 전
not really. that would mean its been up and down, up and down. this is nothing but down..
👍️0
Fat Thor Fat Thor 5 년 전
...this price action is ALL over the place. Crazy.
👍️0
alchemytrader alchemytrader 5 년 전
man i hope so. just want out even now
👍️0
BoilerRoom BoilerRoom 5 년 전
$ZFGN in at .70
👍️0
BoilerRoom BoilerRoom 5 년 전
Short this
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
will recover but sucks,waste of time
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
dont think so
👍️0
Widowsson32 Widowsson32 5 년 전
This is done no benefit to this company but ONTX will make you very rich
👍️0
alchemytrader alchemytrader 5 년 전
institutions selling off?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
the news is great,why?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
fffffffffffffffffff MMS
👍️0
alchemytrader alchemytrader 5 년 전
i guess were screwed
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
f MMs
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
.79 f
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 년 전
what the heck is going on here?
👍️0

최근 히스토리

NASDAQ
LRMR
Larimar Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지